MX2015016456A - Composicion farmaceutica, preparacion y sus usos. - Google Patents
Composicion farmaceutica, preparacion y sus usos.Info
- Publication number
- MX2015016456A MX2015016456A MX2015016456A MX2015016456A MX2015016456A MX 2015016456 A MX2015016456 A MX 2015016456A MX 2015016456 A MX2015016456 A MX 2015016456A MX 2015016456 A MX2015016456 A MX 2015016456A MX 2015016456 A MX2015016456 A MX 2015016456A
- Authority
- MX
- Mexico
- Prior art keywords
- interest
- compound
- nanoparticle
- pharmaceutical composition
- subject
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Inorganic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica que comprende la combinación de (i) una nanopartícula biocompatible y de (ii) un compuesto farmacéutico de interés, para administrarse a un sujeto que necesita de dicho compuesto de interés, en el que la nanopartícula potencia la eficacia del compuesto de interés. La dimensión más larga de la nanopartícula biocompatible está normalmente entre aproximadamente 4 y aproximadamente 500 nm, y el valor absoluto de su carga superficial es de al menos 10 mV (|110 m V|). La invención se refiere también a dicha composición para su uso en la administración del compuesto de interés a un sujeto que lo necesita, en la que la nanopartícula y el compuesto de interés se van a administrar a dicho sujeto entre más de 5 minutos y aproximadamente 72 horas entre sí.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361828794P | 2013-05-30 | 2013-05-30 | |
| EP13305712 | 2013-05-30 | ||
| PCT/EP2014/061296 WO2014191569A1 (en) | 2013-05-30 | 2014-05-30 | Pharmaceutical composition, preparation and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015016456A true MX2015016456A (es) | 2016-03-03 |
Family
ID=48656009
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015016456A MX2015016456A (es) | 2013-05-30 | 2014-05-30 | Composicion farmaceutica, preparacion y sus usos. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10413509B2 (es) |
| EP (1) | EP3003288A1 (es) |
| JP (1) | JP6387400B2 (es) |
| KR (1) | KR102245421B1 (es) |
| CN (2) | CN105407878A (es) |
| AU (1) | AU2014273043B2 (es) |
| BR (1) | BR112015029853A2 (es) |
| CA (1) | CA2913023C (es) |
| EA (1) | EA038671B1 (es) |
| HK (1) | HK1222563A1 (es) |
| MA (1) | MA38687A1 (es) |
| MX (1) | MX2015016456A (es) |
| NZ (1) | NZ714273A (es) |
| SG (1) | SG11201509436TA (es) |
| UA (1) | UA116380C2 (es) |
| WO (1) | WO2014191569A1 (es) |
| ZA (1) | ZA201509307B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA029635B1 (ru) | 2011-12-16 | 2018-04-30 | Нанобиотикс | Применение наночастицы, включающей металлический материал, покрытый материалом оксида гафния, в онкологии и композиция, ее содержащая |
| UA116380C2 (uk) | 2013-05-30 | 2018-03-12 | Нанобіотікс | Посилення терапевтичної або профілактичної ефективності фармацевтичної сполуки |
| JP6789960B2 (ja) * | 2014-11-25 | 2020-11-25 | キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ | 医薬組成物、その調製及び使用 |
| HUE062561T2 (hu) * | 2014-11-25 | 2023-11-28 | Curadigm Sas | Legalább két eltérõ nanorészecskéket és egy gyógyászati vegyületet kombináló gyógyászati készítmény, annak elõállítása és alkalmazásai |
| ES2774365T3 (es) * | 2014-11-25 | 2020-07-20 | Curadigm Sas | Composición farmacéutica, preparación y usos de la misma |
| ES2890662T3 (es) | 2014-11-25 | 2022-01-21 | Curadigm Sas | Composiciones farmacéuticas, preparación y usos de las mismas |
| EP3258917B1 (en) * | 2015-02-19 | 2022-12-21 | Carnegie Mellon University | Methods to reduce toxicities and to improve bioavailabilities of nanodrugs |
| MA43100A (fr) | 2015-05-28 | 2018-09-05 | Nanobiotix | Nanoparticules à utiliser en tant que vaccin thérapeutique |
| CN105055447B (zh) * | 2015-06-23 | 2018-03-13 | 中南大学湘雅二医院 | 氧化铁纳米颗粒用于制备改善厄洛替尼耐药性药物的应用 |
| CN108969757B (zh) * | 2018-07-11 | 2021-07-27 | 浙江大学 | 负载microRNA的氧化铈纳米复合水凝胶及制备方法和应用 |
| CN110498607B (zh) * | 2019-08-21 | 2022-03-08 | 中国科学院上海硅酸盐研究所 | 一种多功能钙硅基稀土掺杂的生物活性粉体及其制备方法和应用 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4280918A (en) | 1980-03-10 | 1981-07-28 | International Business Machines Corporation | Magnetic particle dispersions |
| US20030186869A1 (en) * | 1990-05-14 | 2003-10-02 | George Poiani | Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor |
| US6686332B1 (en) * | 1993-10-15 | 2004-02-03 | Xoma Corporation | Method of treating depressed reticuloendothelial system function |
| GB9509321D0 (en) | 1995-05-09 | 1995-06-28 | Zylepsis Ltd | Methods of and substances for inhibiting oxidative enzymes |
| US6160006A (en) | 1996-10-18 | 2000-12-12 | Wayne State University | 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor in grapefruit |
| JPH10120597A (ja) | 1996-10-22 | 1998-05-12 | Eiken Chem Co Ltd | リンパ節高集積性コロイド粒子 |
| EP1007034B1 (en) | 1997-08-19 | 2003-11-05 | Warner-Lambert Company LLC | Compositions containing bergamottin for increasing the oral bioavailability of pharmaceutical agents |
| US20040166060A1 (en) * | 2000-06-16 | 2004-08-26 | Sloan Kettering Institute For Cancer Research | Liposomal encapsulation of alpha particle emittors and uses thereof |
| ATE309786T1 (de) * | 2000-06-30 | 2005-12-15 | Inex Pharmaceuticals Corp | Liposomale antineoplastische arzneimittel und deren verwendungen |
| US8178123B2 (en) | 2001-08-29 | 2012-05-15 | Femina Pharma Incorporated | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration |
| US20050090732A1 (en) * | 2003-10-28 | 2005-04-28 | Triton Biosystems, Inc. | Therapy via targeted delivery of nanoscale particles |
| CA2547024C (en) * | 2003-12-22 | 2013-12-17 | Bracco Research Sa | Gas-filled microvesicle assembly for contrast imaging |
| WO2005086639A2 (en) | 2004-02-10 | 2005-09-22 | Barnes-Jewish Hospital | Improved efficacy and safety of targeted particulate agents with decoy systems |
| US20060264804A1 (en) | 2005-04-07 | 2006-11-23 | Yoram Karmon | Device and kit for delivery of encapsulated substances and methods of use thereof |
| WO2006127962A2 (en) * | 2005-05-25 | 2006-11-30 | Becton, Dickinson And Comapny | Particulate formulations for intradermal delivery of biologically active agents |
| DE102005039579B4 (de) | 2005-08-19 | 2022-06-30 | Magforce Ag | Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen |
| EP2000150B1 (en) | 2006-03-24 | 2016-07-13 | Toto Ltd. | Titanium oxide complex particle, dispersion solution of the particle, and process for production of the particle |
| US20100233219A1 (en) | 2006-03-30 | 2010-09-16 | Fujifilm Corporation | Inorganic nanoparticle compromising an active substance immobilized on the surface and a polymer |
| US20090181076A1 (en) | 2006-05-04 | 2009-07-16 | University Of South Australia | Drug Release From Nanoparticle-Coated Capsules |
| MX2010002100A (es) | 2007-08-21 | 2010-03-26 | Alza Corp | Composiciones de liposomas para administracion in vivo de compuestos de acido boronico. |
| FR2922106B1 (fr) | 2007-10-16 | 2011-07-01 | Univ Claude Bernard Lyon | Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants. |
| US20100272639A1 (en) | 2007-12-21 | 2010-10-28 | John Robert Dutcher | Polysaccharide nanoparticles |
| US9403789B2 (en) | 2008-02-21 | 2016-08-02 | Sequoia Pharmaceuticals, Inc. | Benzofuran-containing amino acid inhibitors of cytochrome P450 |
| WO2009142754A1 (en) | 2008-05-22 | 2009-11-26 | Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dendritic conjugates and methods of use |
| EP2130553A1 (en) | 2008-06-05 | 2009-12-09 | Nanobiotix | Inorganic nanoparticles of high density to destroy cells in-vivo |
| WO2010048623A2 (en) | 2008-10-26 | 2010-04-29 | Board Of Regents, The University Of Texas Systems | Medical and imaging nanoclusters |
| EP2275137A1 (en) * | 2009-07-10 | 2011-01-19 | Nanobiotix | Metallic nanoparticles, preparation and uses thereof |
| GB0921596D0 (en) | 2009-12-09 | 2010-01-27 | Isis Innovation | Particles for the treatment of cancer in combination with radiotherapy |
| JP2013518602A (ja) * | 2010-02-09 | 2013-05-23 | サンガモ バイオサイエンシーズ， インコーポレイテッド | 部分的に一本鎖のドナー分子による標的化ゲノム改変 |
| US8580312B2 (en) | 2010-02-17 | 2013-11-12 | National University Corporation Kobe University | Radiation therapy agent |
| KR101786142B1 (ko) | 2010-03-26 | 2017-10-17 | 아브락시스 바이오사이언스, 엘엘씨 | 간세포 암종의 치료 방법 |
| GB201009455D0 (en) * | 2010-06-04 | 2010-07-21 | King S College London | Nanoparticles and their uses in molecular imaging |
| US9782342B2 (en) | 2010-10-11 | 2017-10-10 | Wichita State University | Composite magnetic nanoparticle drug delivery system |
| CA2816155C (en) | 2010-12-17 | 2020-10-27 | Arrowhead Research Corporation | Galactose cluster-pharmacokinetic modulator targeting moiety for sirna |
| US20140227343A1 (en) | 2011-01-31 | 2014-08-14 | Centre National De La Recherche Scientifique | Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles |
| DK2670394T3 (en) | 2011-01-31 | 2019-01-14 | Nanobiotix | NANOPARTICLE DELIVERY SYSTEMS, PREPARATION AND APPLICATIONS THEREOF |
| US20120237566A1 (en) * | 2011-03-15 | 2012-09-20 | Venture Isles, LLC | Inhibiting stomach-acid release, reducing inflammation and preventing and treating cancer: compositions and methods of use |
| US10251841B2 (en) | 2011-10-17 | 2019-04-09 | Trustees Of Boston University | Polymeric depots for localization of agent to biological sites |
| CN102532154B (zh) | 2012-01-11 | 2014-05-14 | 昆明医学院 | 隆萼当归线型呋喃香豆素化合物及其应用 |
| WO2014039874A2 (en) | 2012-09-07 | 2014-03-13 | Carnegie Mellon University | Methods and materials for reducing reticuloendothelial system clearance of particles from a subject |
| ITRM20120480A1 (it) | 2012-10-09 | 2014-04-10 | Uni Degli Studi Camerino | Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione. |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| UA116380C2 (uk) | 2013-05-30 | 2018-03-12 | Нанобіотікс | Посилення терапевтичної або профілактичної ефективності фармацевтичної сполуки |
| EP2886128A1 (en) | 2013-12-20 | 2015-06-24 | Nanobiotix | Pharmaceutical composition comprising nanoparticles, preparation and uses thereof |
| ES2774365T3 (es) | 2014-11-25 | 2020-07-20 | Curadigm Sas | Composición farmacéutica, preparación y usos de la misma |
| ES2890662T3 (es) | 2014-11-25 | 2022-01-21 | Curadigm Sas | Composiciones farmacéuticas, preparación y usos de las mismas |
| HUE062561T2 (hu) | 2014-11-25 | 2023-11-28 | Curadigm Sas | Legalább két eltérõ nanorészecskéket és egy gyógyászati vegyületet kombináló gyógyászati készítmény, annak elõállítása és alkalmazásai |
| JP6789960B2 (ja) | 2014-11-25 | 2020-11-25 | キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ | 医薬組成物、その調製及び使用 |
| TW201628639A (zh) | 2014-11-25 | 2016-08-16 | 奈諾生技公司 | 醫藥組合物、其製備及其用途 |
-
2014
- 2014-05-30 UA UAA201513039A patent/UA116380C2/uk unknown
- 2014-05-30 MX MX2015016456A patent/MX2015016456A/es active IP Right Grant
- 2014-05-30 CN CN201480031188.4A patent/CN105407878A/zh active Pending
- 2014-05-30 AU AU2014273043A patent/AU2014273043B2/en active Active
- 2014-05-30 CA CA2913023A patent/CA2913023C/en active Active
- 2014-05-30 BR BR112015029853A patent/BR112015029853A2/pt not_active Application Discontinuation
- 2014-05-30 CN CN202010861645.XA patent/CN112107558A/zh active Pending
- 2014-05-30 NZ NZ714273A patent/NZ714273A/en unknown
- 2014-05-30 EP EP14727810.5A patent/EP3003288A1/en active Pending
- 2014-05-30 WO PCT/EP2014/061296 patent/WO2014191569A1/en active Application Filing
- 2014-05-30 MA MA38687A patent/MA38687A1/fr unknown
- 2014-05-30 JP JP2016516193A patent/JP6387400B2/ja active Active
- 2014-05-30 EA EA201592279A patent/EA038671B1/ru unknown
- 2014-05-30 SG SG11201509436TA patent/SG11201509436TA/en unknown
- 2014-05-30 US US14/892,271 patent/US10413509B2/en active Active
- 2014-05-30 KR KR1020157036985A patent/KR102245421B1/ko active IP Right Grant
-
2015
- 2015-12-22 ZA ZA2015/09307A patent/ZA201509307B/en unknown
-
2016
- 2016-09-12 HK HK16110781.4A patent/HK1222563A1/zh unknown
-
2019
- 2019-08-29 US US16/554,765 patent/US11357724B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160013212A (ko) | 2016-02-03 |
| JP6387400B2 (ja) | 2018-09-05 |
| SG11201509436TA (en) | 2015-12-30 |
| AU2014273043A1 (en) | 2015-12-03 |
| UA116380C2 (uk) | 2018-03-12 |
| NZ714273A (en) | 2019-04-26 |
| US20160184225A1 (en) | 2016-06-30 |
| JP2016522833A (ja) | 2016-08-04 |
| US11357724B2 (en) | 2022-06-14 |
| BR112015029853A2 (pt) | 2017-07-25 |
| EP3003288A1 (en) | 2016-04-13 |
| EA201592279A1 (ru) | 2016-06-30 |
| KR102245421B1 (ko) | 2021-04-29 |
| HK1222563A1 (zh) | 2017-07-07 |
| CN105407878A (zh) | 2016-03-16 |
| CA2913023A1 (en) | 2014-12-04 |
| CA2913023C (en) | 2021-06-08 |
| EA038671B1 (ru) | 2021-10-01 |
| CN112107558A (zh) | 2020-12-22 |
| US20200009050A1 (en) | 2020-01-09 |
| WO2014191569A1 (en) | 2014-12-04 |
| MA38687A1 (fr) | 2017-12-29 |
| US10413509B2 (en) | 2019-09-17 |
| ZA201509307B (en) | 2017-04-26 |
| AU2014273043B2 (en) | 2019-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ714273A (en) | Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof | |
| MX2017006813A (es) | Composicion farmaceutica, preparacion y usos de la misma. | |
| MX2021010595A (es) | Composicion farmaceutica, preparacion y usos de la misma. | |
| WO2017042607A3 (en) | Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain | |
| WO2011099832A3 (en) | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same | |
| EP3904502A3 (en) | Compositions and methods | |
| UA109868C2 (ru) | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) | |
| MX2016005668A (es) | Formas cristalinas de compuestos terapeuticos y sus usos. | |
| CA2894891A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| BR112015023629A2 (pt) | formulação de acetato de abiraterona | |
| NZ602557A (en) | Solid form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | |
| WO2012088266A3 (en) | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 | |
| AR092993A1 (es) | Laquinimod para reducir el daño talamico en la esclerosis multiple | |
| WO2016025933A3 (en) | Substituted polycyclic antibacterial compounds | |
| MY179605A (en) | Use of benzimidazole-proline derivatives | |
| WO2014205199A3 (en) | Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency | |
| CA2929436C (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
| SG10201907291QA (en) | Monomethylfumarate prodrug compositions | |
| PH12015502747A1 (en) | Novel compounds for the treatment of cancer | |
| MX2016000294A (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. | |
| WO2014182789A3 (en) | Radiomitigating pharmaceutical formulations | |
| AR102778A1 (es) | Composición farmacéutica, su preparación y sus usos | |
| CL2015002702A1 (es) | Composiciones farmacéuticas micronizadas. | |
| IN2013MU01177A (es) | ||
| EA032913B1 (ru) | Препараты производных пиримидиндиона |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: CURADIGM SAS |
|
| FG | Grant or registration |